Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,041 DKK | +0.74% | +1.90% | -5.29% |
May. 15 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
May. 15 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.29% | 19.21B | |
+9.74% | 115B | |
+11.91% | 106B | |
-2.56% | 21.96B | |
-13.76% | 21.87B | |
-3.39% | 18.08B | |
-38.57% | 17.71B | |
+6.25% | 14.32B | |
+34.55% | 12.42B | |
-24.66% | 8.23B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance